CQDM funds the development of a novel artificial intelligence tool for cardiovascular clinical trialsHome > Press room > CQDM funds the development of a novel artificial intelligence tool for cardiovascular clinical trials
November 5, 2020
A collaboration between Perceiv AI, DalCor Pharmaceuticals and the Montreal Heart Institute
The CQDM is pleased to announce the launch of a $600,000 collaborative project in biopharma and artificial intelligence (AI) to develop an AI-driven precision medicine tool.
the project supports the development of AI-driven digital biomarkers to identify patients who would specifically benefit from given medicines being tested in cardiovascular disease clinical trials.find out more by visiting the Institute’s website